At TCT 2024, Dr. Amar Krishnaswamy presented the latest MRI data analyses which compared flow dynamics and left ventricular function between DurAVR® THV recipients and a matched healthy control group. Here were some of the key takeaways:

• In this matched analysis, DurAVR® THV’s biomimetic design provides flow patterns similar to the healthy valve, as measured by flow displacement (FD) and flow reversal ratios (FRR). 

• LV mass decreased in patients treated with DurAVR® THV compared to baseline, suggesting an improvement in LV unloading.

• In this matched analysis, DurAVR® THV restored left ventricle (LV) end-diastolic volume, LV end-systolic volume, and LV mass to similar to healthy controls.